{
    "organizations": [],
    "uuid": "d45e569c559ea44e7f158fed3c3d6146b147c42d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-announces-discontinuation-of/brief-merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-for-the-treatment-of-people-with-prodromal-alzheimers-disease-idUSFWN1Q31H7",
    "ord_in_thread": 0,
    "title": "Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat For The Treatment Of People With Prodromal Alzheimer’S Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Merck & Co Inc:\n* MERCK ANNOUNCES DISCONTINUATION OF APECS STUDY EVALUATING VERUBECESTAT (MK-8931) FOR THE TREATMENT OF PEOPLE WITH PRODROMAL ALZHEIMER’S DISEASE\n* MERCK & CO INC - ‍EDMC CONCLUDED THAT IT WAS UNLIKELY THAT POSITIVE BENEFIT/RISK COULD BE ESTABLISHED IF TRIAL CONTINUED​\n* MERCK & CO INC - ‍DECISION TO STOP STUDY FOLLOWS A RECOMMENDATION BY EXTERNAL DATA MONITORING COMMITTEE​\n* MERCK & CO INC - ‍IT WILL BE STOPPING PROTOCOL 019, ALSO KNOWN AS APECS STUDY​\n* MERCK & CO INC - ‍STOPPING PROTOCOL 019, ALSO KNOWN AS APECS STUDY, A PHASE 3 STUDY EVALUATING VERUBECESTAT (MK-8931)​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T05:39:00.000+02:00",
    "crawled": "2018-02-14T12:48:54.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "announces",
        "discontinuation",
        "apecs",
        "study",
        "evaluating",
        "verubecestat",
        "treatment",
        "people",
        "prodromal",
        "alzheimer",
        "disease",
        "merck",
        "co",
        "inc",
        "concluded",
        "unlikely",
        "positive",
        "could",
        "established",
        "trial",
        "merck",
        "co",
        "inc",
        "stop",
        "study",
        "follows",
        "recommendation",
        "external",
        "data",
        "monitoring",
        "merck",
        "co",
        "inc",
        "stopping",
        "protocol",
        "also",
        "known",
        "apecs",
        "merck",
        "co",
        "inc",
        "protocol",
        "also",
        "known",
        "apecs",
        "study",
        "phase",
        "study",
        "evaluating",
        "verubecestat",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}